Диссертация (1141216), страница 15
Текст из файла (страница 15)
№ 4 (59). C. 251–264.44. McCarthy G.M. [и др.]. Factors associated with increased frequency of HIVrelated oral candidiasis // J Oral Pathol Med. 1991. № 7 (20). C. 332–336.45. McCarthy G.M. Host factors associated with HIV-related oral candidiasis. A109review // Oral Surgery, Oral Medicine, Oral Pathology. 1992. Т. 73. № 2. 181–186 с.46.
McIlroy M.A. Failure of fluconazole to suppress fungemia in a patient withfever, neutropenia, and typhlitis. // The Journal of infectious diseases. 1991. № 2 (163).C. 420–1.47. Méar J.-B. [и др.]. Candida albicans and Pseudomonas aeruginosainteractions: More than an opportunistic criminal association? // Médecine et MaladiesInfectieuses. 2013. № 4 (43). C.
146–151.48. Menezes R. de P. [и др.]. Related factors for colonization by candida speciesin the oral cavity of HIV-infected individuals. // Revista do Instituto de MedicinaTropical de Sao Paulo. 2015. № 5 (57). C. 413–9.49. Mikulska M., del Bono V., Ratto S.
V.C. Occurrence, presentation andtreatment of candidemia // Expert Review of Clinical Immunology. 2012. (8). C. 755–765.50. Moore RD C.R. Natural history of opportunistic disease in an HIV-infectedurban clinical cohort. 1996. 124:633-42. с.51. Muadcheingka T., Tantivitayakul P. Distribution of Candida albicans andnon-albicans Candida species in oral candidiasis patients: Correlation between cellsurface hydrophobicity and biofilm forming activities // Archives of Oral Biology.2015.
№ 6 (60). C. 894–901.52. Mukherjee P.K., Chandra J. Candida Biofilms: Development, Architecture,and Resistance // Microbiology Spectrum. 2015. № 4 (3).53. Mulu A. [и др.]. Frequent detection of ‘azole’ resistant Candida speciesamong late presenting AIDS patients in northwest Ethiopia // BMC Infectious Diseases.2013. № 1 (13). C. 82.54. Mushi M.F.
[и др.]. High Oral Carriage of Non-albicans Candida spp. amongHIV-infected individuals // International Journal of Infectious Diseases. 2016. (49). C.185–188.55. Nash A.K. [и др.]. The gut mycobiome of the Human Microbiome Projecthealthy cohort. // Microbiome. 2017. № 1 (5). C. 153.56.
Negri M. [и др.]. Insights into Candida tropicalis nosocomial infections and110virulence factors // European Journal of Clinical Microbiology & Infectious Diseases.2012. № 7 (31). C. 1399–1412.57. Neville B.A. Candida albicans commensalism in the gastrointestinal tract //FEMS Yeast Research. 2015. № 7 (15). C. fov081.58. Owotade F.J., Patel M. Virulence of oral Candida isolated from HIV-positivewomen with oral candidiasis and asymptomatic carriers // Oral Surgery, Oral Medicine,Oral Pathology and Oral Radiology. 2014. № 4 (118). C. 455–460.59. Oxman D.A.
[и др.]. Candidaemia associated with decreased in vitrofluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?// Journal of Antimicrobial Chemotherapy. 2010. № 7 (65). C. 1460–1465.60. Pang W. [и др.]. Prevalence of Opportunistic Infections and Causes of Deathamong Hospitalized HIV-Infected Patients in Sichuan, China // The Tohoku Journal ofExperimental Medicine. 2018. № 3 (244). C. 231–242.61. Pappas P.G. [и др.]. Guidelines for Treatment of Candidiasis // ClinicalInfectious Diseases.
2004. № 2 (38). C. 161–189.62. Patel P.K. [и др.]. The Changing Epidemiology of Oropharyngeal Candidiasisin Patients with HIV/AIDS in the Era of Antiretroviral Therapy // AIDS Research andTreatment. 2012. (2012). C. 1–5.63. Paula S.B. de [и др.]. Oral Candida colonization in HIV-infected patients inLondrina-PR, Brazil: antifungal susceptibility and virulence factors.
// Journal ofinfection in developing countries. 2015. № 12 (9). C. 1350–9.64. Pemán J., Quindós G. Aspectos actuales de las enfermedades invasorascausadas por Candida y otros hongos levaduriformes // Revista Iberoamericana deMicología. 2016. № 3 (33). C. 133–139.65. Pfaller M.A. [и др.]. Epidemiology and outcomes of invasive candidiasis dueto non-albicans species of Candida in 2,496 patients: data from the ProspectiveAntifungal Therapy (PATH) registry 2004-2008. // PloS one. 2014.
№ 7 (9). C.e101510.66. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing ofCandida spp. by use of Clinical and Laboratory Standards Institute broth microdilution111methods, 2010 to 2012. // Journal of clinical microbiology. 2012. № 9 (50). C. 2846–56.67. Polke M., Hube B., Jacobsen I.D.
Candida Survival Strategies 2015. 139–235с.68. Pons V., Greenspan D., Debruin M. Therapy for oropharyngeal candidiasis inHIV-infected patients: a randomized, prospective multicenter study of oral fluconazoleversus clotrimazole troches. The Multicenter Study Group.
// Journal of acquiredimmune deficiency syndromes. 1993. № 12 (6). C. 1311–6.69. Powderly W.G., Robinson K., Keath E.J. Molecular typing of Candidaalbicans isolated from oral lesions of HIV-infected individuals // AIDS. 1992. № 1 (6).C. 81–84.70. Prescott R.J., Harris M., Banerjee S.S. Fungal infections of the small andlarge intestine. // Journal of clinical pathology. 1992. № 9 (45). C.
806–811.71. Reinhardt S.W. [и др.]. AIDS-Defining Illnesses at Initial Diagnosis of HIVin a Large Guatemalan Cohort. // Open forum infectious diseases. 2017. № 4 (4). C.ofx249.72. Rex J.H. [и др.]. Development of interpretive breakpoints for antifungalsusceptibility testing: conceptual framework and analysis of in vitro-in vivo correlationdata for fluconazole, itraconazole, and candida infections. Subcommittee on AntifungalSusceptibility Testing of the National Committee for Clinical Laboratory Standards.
//Clinical infectious diseases : an official publication of the Infectious Diseases Society ofAmerica. 1997. № 2 (24). C. 235–47.73. Rubaihayo J. [и др.]. Frequency and distribution patterns of opportunisticinfections associated with HIV/AIDS in Uganda. // BMC research notes.
2016. № 1 (9).C. 501.74. Samaranayake L.P. Oral mycoses in HIV infection // Oral Surgery, OralMedicine, Oral Pathology. 1992. № 2 (73). C. 171–180.75. Sánchez-Vargas L.O. [и др.]. Oral Candida isolates colonizing or infectinghuman immunodeficiency virus-infected and healthy persons in Mexico.
// Journal ofclinical microbiology. 2005. № 8 (43). C. 4159–62.76. Santiwongkarn P. [и др.]. Prevalence of oral Candida carriage in Thai112adolescents // Journal of Investigative and Clinical Dentistry. 2012. № 1 (3). C. 51–55.77. Santos Abrantes P.M. dos, McArthur C.P., Africa C.W.J. Multi-drug resistantoral Candida species isolated from HIV-positive patients in South Africa and Cameroon// Diagnostic Microbiology and Infectious Disease.
2014. № 2 (79). C. 222–227.78. Schuman P. [и др.]. Weekly fluconazole for the prevention of mucosalcandidiasis in women with HIV infection. A randomized, double-blind, placebocontrolled trial. Terry Beirn Community Programs for Clinical Research on AIDS. //Annals of internal medicine. 1997. № 9 (126). C. 689–96.79. Schuman P. [и др.]. Mucosal candidal colonization and candidiasis in womenwith or at risk for human immunodeficiency virus infection. HIV EpidemiologyResearch Study (HERS) Group. // Clinical infectious diseases : an official publication ofthe Infectious Diseases Society of America. 1998. № 5 (27).
C. 1161–7.80. Selik R.M., Starcher E.T., Curran J.W. Opportunistic diseases reported inAIDS patients: frequencies, associations, and trends. // AIDS (London, England). 1987.Т. 1. № 3. 175–82 с.81. Silva B.V. da [и др.]. Species Distribution, Virulence Factors, and AntifungalSusceptibility Among Candida parapsilosis Complex Isolates Recovered from ClinicalSpecimens // Mycopathologia. 2015. № 5–6 (180). C. 333–343.82. Simon J.
[и др.]. Echinocandins in invasive candidiasis // Mycoses. 2013. №6 (56). C. 601–609.83. Smith D.E. [и др.]. Itraconazole versus ketaconazole in the treatment of oraland oesophageal candidosis in patients infected with HIV. // AIDS (London, England).1991. № 11 (5). C. 1367–71.84. Sociedade Brasileira de Infectologia. A.L. [и др.]. The Brazilian journal ofinfectious diseases.
/ A.L. Sociedade Brasileira de Infectologia., T. Guimarães, L.F.A.Camargo, R. Richtmann, F. de Queiroz-Telles [и др.]., Elsevier Editora Lrda, 2013.283-312 c.85. Stock I. Fungal diseases of vulva and vagina caused by Candida species //Medizinische Monatsschrift fur Pharmazeuten. 2010. № 9 (33). C.
324–326.86. Stuehler C. [и др.]. Immune recovery in HIV-infected patients after Candida113esophagitis is impaired despite long-term antiretroviral therapy // AIDS. 2016. № 12(30). C. 1923–1933.87. Tachikawa N., Yasuoka A., Oka S. Improvement of onychomycosis withoutantifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in anHIV-infected patient. // Japanese journal of infectious diseases. 1999.
№ 6 (52). C. 245–6.88. Taff H.T. [и др.]. Mechanisms of Candida biofilm drug resistance // FutureMicrobiology. 2013. № 10 (8). C. 1325–1337.89. Telenti A., Zanger U.M. Pharmacogenetics of Anti-HIV Drugs // AnnualReview of Pharmacology and Toxicology. 2008.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
